{"ticker": {"uuid": "06fdbd49-6beb-4fe5-af7c-28dae251ae49", "symbol": "DMAA", "name": "Drugs Made In America Acquisition Corp. Ordinary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Financial Services", "industry": "Shell Companies"}, "articles": [{"title": "Drugs Made In America Acquisition Corp (DMAA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Drugs Made In America Acquisition Corp (DMAA), focusing on its profitability and balance sheet. It notes that relevant financial data regarding cash, assets, liabilities, free cash flow, revenue, operating profit, and operation", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T17:41:30", "published_display": "18 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp", "summary": "This article provides an overview of Drugs Made In America Acquisition Corp (DMAA), including its current stock price, market capitalization, and P/E ratio. It notes that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:36", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAAR) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Drugs Made In America Acquisition Corp (DMAAR), including its stock price, market cap, and various institutional shareholdings. It lists major institutional investors and their shareholdings, as well as changes in t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaar/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:58", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAAU) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Drugs Made In America Acquisition Corp (DMAAU), detailing its current stock price, market cap, and indicating that relevant valuation data like P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. It briefly outlines t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaau/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:32", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAAU) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Drugs Made In America Acquisition Corp (DMAAU) focusing on its institutional confidence. It lists key institutional shareholders and their recent activity, showing both increases and decreases in shares held. The data highlight", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaau/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:32", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAAU) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Drugs Made In America Acquisition Corp (DMAAU), detailing various risk metrics such as volatility, maximum drawdown, and return-to-drawdown ratios. It presents a quantitative overview of the stock's risk profile based on metrics like be", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaau/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:32", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAAU) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Drugs Made In America Acquisition Corp (DMAAU), focusing on its profitability and balance sheet. However, the report indicates that relevant financial data for profitability, operational efficiency, growth potential, and shareh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaau/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:32", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBrUEd1QU54WTZiNzRJRUtaYzRsb2RkdDRnc2tfaV83NDVEdVBoVWM5bE1iRHlWU2NnTEhLWWZvZXphSHMtUVFkSm9QWmc5eGV5UUhZTGNGOGtKZldFcnpseWk5RV93cFhaVmNrY3daMW13dGlZRHcwSg?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T01:52:16+00:00", "published_display": "18 Jun 2026 01:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Drugs Made In America Acquisition Corp (DMAA), including its current market data, P/E ratio, and market capitalization. It highlights that relevant data for financial forecasting, such as EPS, Revenue, and Net Profit, have not yet be", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:25", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Drugs Made In America Acquisition Corp (DMAA), focusing on changes in institutional shareholding. It lists key shareholders and their recent activity, including increases and decreases in shares held by major invest", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:25", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Ord Shs (DMII) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTFBncnYwQkdHeW1vYVBUNU1JWS11bWxlUlR6Tk5RY2N5cWZrb0ZGamMtb01vdmpyc1gwT2cyQ1A0VkctMGhkMjRwUzNnYW0zYUZsd2ZHTTE5RE9VOTJoNENHN0hzM25ELWJBNng5WDRnY3Y?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T22:54:11+00:00", "published_display": "17 Jun 2026 22:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Drugs Made", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-17T23:39:32", "published_display": "17 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Drugs Made In America Acquisition Corp (DMAA), focusing on its PE, PB, and fair value. It notes that relevant data for these metrics have not yet been disclosed by the company. The company closed at $10.620 with a market cap of $257.8", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:25", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Drugs Made In America Acquisition Corp (DMAA), listing major shareholders and their respective proportions. It also presents institutional shareholding data over several quarters and reports on significant shareholder activities i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:32", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Units (DMIIU) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE1vcTZLeEdsd0J2UGplQ1JrNTJ5VTllTUpkZFJYejQ0Z1ZPVDFFTERhc3B1elNYMDMtYnc0YUY1ekhIcjI3SFhtYXdkcEJTSUtOQkhfeU1GX0p5ODZ3N0V0VkdKVG1EUndQSGtnUEptOF8xUQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T08:47:40+00:00", "published_display": "17 Jun 2026 08:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) and Power Analytics Global Corp Announce Definitive $1B AI Merger Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOOUdRXzBpTzM2NzlfOE1hT2hJaUxpd3VEODZ4Yjl3eDBidW9WdURwOXU3QVA4c3AxQ3lMaDdGVFhpNThiTGxpV2tRNzRMNzM0WFhwNThWOTNlX1Via0ZHay1hZVhUNlA4WW55eEM1dU1MbllHbnlOMEMtcGdmZjg2UTZ5bmJQRjVBS0J3bTFtQjJZTTFYMkdpMWNlelByX1llSXlzMkx2bmtxRU9QeUN5TC0zX3VOak1MNmtUS1J3enlHSnd6Z2ZnTmpTejBtQjl5VUwyMFY2cy0yNnc3UmJCcUM1dnVKWWtiZWpuNmV5OFI?oc=5", "source_name": "Minichart", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition to Merge With Power Analytics Global in Deal Valued Up to $1 Billion", "summary": "Drugs Made In America Acquisition (DMAA) has entered into a Definitive Merger Agreement with Power Analytics Global (PAGC), an AI and cybersecurity company. The deal values PAGC at up to $1 billion, with a floor valuation of $300 million, and is intended to take PAGC public. Post", "url": "https://www.tradingview.com/news/tradingview:e2b78c838864c:0-drugs-made-in-america-acquisition-to-merge-with-power-analytics-global-in-deal-valued-up-to-1-billion/", "source_name": "TradingView", "published_at": "2026-05-05T23:38:43", "published_display": "05 May 2026 23:38", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMAAR Price History for Drugs Made IN America Acquisition Corp. Rights Stock", "summary": "This Barchart.com page provides detailed price history information for Drugs Made IN America Acquisition Corp. Rights (DMAAR) stock. It includes tabs for end-of-day prices, latest trades, and corporate actions, with options for members to download historical data. The page also f", "url": "https://www.barchart.com/stocks/quotes/DMAAR/price-history", "source_name": "Barchart", "published_at": "2026-04-21T08:09:32", "published_display": "21 Apr 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made in America Acquisition Corp. signs LOI for de-SPAC with Power Analytics", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOVGhZakR2ZW5iU2FSYzNCU2xCbVlaWFFRb3NtZmlhS1hNR3lTR1pPUk5xWktubmg3NV9MaUM4VGRIUkRFZ2o5VGthZTIyci1RcWhDSkRIaGFHWTNMZmRaZm41RUZfT0hDSk83YmYtemdTbmxxT2lZci1TN3NwWVRwV3Q2akE2a0ZtOHNVRE93VEFoYzFBRGZvb19NMGp5eXE1cTA2NlhaZEM1YVBDZEN4UzhUUURWWm94VUJZZkVTR0tmbkMyU0lxMTZKMmw1Vmk4ZXc?oc=5", "source_name": "Investing.com", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prudential Earnings: Headline Numbers Make the Market Skeptical; Shares Fairly Valued", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOLXpWLThmYURNcnJBLXZQNTlRUy1NSmQ4NkVVX0pQRzlfUFFtVFJkNDJqN1FFYWZLWS1xSmd5S3dNUU42cjFLOUdiWTkxdXhvZXg1UlFtZmtVZG1qN2w4QWxXZEJsbFJ2QUQtVUIxMWJ4Z1l3djBiNFp3MEdhbkh6cUtlWVB5b2RNZXZudmhPbWI3RkF0NmhxdF9aQmppbUFHOThtZDlBU3Vsak9fX0pKUGotdHNBaDkzODRZbGdUUVc?oc=5", "source_name": "Morningstar", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMAAR SEC Filings - Drugs Made In Amer Acqutn Corp 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTFA0ZEdQMlQ3Nnl0dXJYYUdnYWQ3RkZ0VEtjNGYtd09oMUkzbUZqVVRJaE1BMnM2R1h0NlQ0Tk16OUVraHI0cTBkaDk0anRZWmlWTXZTMk1TdFA?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-06T15:37:01+00:00", "published_display": "06 Mar 2026 15:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition (NASDAQ:DMAA) Trading Up 0.2% - Time to Buy?", "summary": "Drugs Made In America Acquisition (NASDAQ: DMAA) rose 0.2% to $10.40 during midday trading on Tuesday but traded well below its average daily volume. Analyst sentiment is predominantly negative, with Weiss Ratings reaffirming a \"Sell (D-)\" rating. Despite this, several institutio", "url": "https://www.marketbeat.com/instant-alerts/drugs-made-in-america-acquisition-nasdaqdmaa-trading-up-02-time-to-buy-2026-01-14/", "source_name": "MarketBeat", "published_at": "2026-01-14T07:58:29", "published_display": "14 Jan 2026 07:58", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) is largely controlled by institutional shareholders who own 79% of the company", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPa3VmcmlGOGwwYUlSWmNsZzRsMnU1b3hPWENLZkRydklBT25SUmRGMXg1Q2h3TnhoWUJGekNBQW5oUzlGOGNQam9RRTg4UkpvUDRHVWtBdDJwVzUzcEhNR3FoWDlWWkFUZFpZZDBsaHVXQ01PUWJ3ZlpuV1R0djRnSW5QcVhzUQ?oc=5", "source_name": "Market source", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. Announces the Separate Trading of its Ordinary Shares and Rights Commencing December 3, 2025", "summary": "Drugs Made In America Acquisition II Corp. announced that, effective December 3, 2025, holders of its units from the initial public offering can trade ordinary shares and rights separately on the Nasdaq Global Market. Each unit comprises one ordinary share and a right to receive ", "url": "https://www.8newsnow.com/business/press-releases/globenewswire/9596034/drugs-made-in-america-acquisition-ii-corp-announces-the-separate-trading-of-its-ordinary-shares-and-rights-commencing-december-3-2025", "source_name": "KLAS 8 News Now", "published_at": "2025-12-03T06:34:00", "published_display": "03 Dec 2025 06:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp. SEC 10-Q Report", "summary": "Drugs Made In America Acquisition Corp. (DMAA) has released its Q3 2025 Form 10-Q report, detailing financial performance and operational progress. The blank check company, focused on the pharmaceutical industry, reported a net income of $2.18 million for the quarter, primarily f", "url": "https://www.tradingview.com/news/tradingview:8cc2be0240140:0-drugs-made-in-america-acquisition-corp-sec-10-q-report/", "source_name": "TradingView", "published_at": "2025-11-19T05:37:23", "published_display": "19 Nov 2025 05:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. SEC 10-Q Report", "summary": "Drugs Made In America Acquisition II Corp. (DMIIU), a blank check company, has released its Form 10-Q report for Q3 2025, detailing a net loss of $46,158 for the quarter and $143,558 for the nine months ended September 30, 2025. The company, which completed its IPO in September 2", "url": "https://www.tradingview.com/news/tradingview:5f14fb6106821:0-drugs-made-in-america-acquisition-ii-corp-sec-10-q-report/", "source_name": "TradingView", "published_at": "2025-11-19T05:37:23", "published_display": "19 Nov 2025 05:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMIIU Stock Price, News & Analysis | Drugs Made In America Acquisition II", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTFBGU2Y4dVVTM3gwWEJyem96UGtIbWZEelBIZ184NDMyNHNWTkxVc09ncnFWZUNEZDhuYmJZMVRaM0hiVUl1VUZhLWFmSWhJM2VpbFJJaQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-09-25T11:28:45+00:00", "published_display": "25 Sep 2025 11:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition (DMAA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5va2pWcm8xT3NBTnQxNjJVUW0zck9FUXJHcGNSNjV3SV9RVHRpZlgybHRwY2hPVmdVTy0zbUY5aFZBazhsUTR2X1VoWG1WbnRJS3RfOXRMd1JOZw?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-24T23:55:47+00:00", "published_display": "24 Jul 2025 23:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition (DMAA) Institutional Ownership 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE5UYkV5QVpnRktjRm5EWTNYcndENXM5MXpsb2xRbmE2elAyRWJPa2lyMHl2WmZlcng2MlNlMHRPNk5aekNjM0dRVTF1ZUtwUUVhVDdaekgzdVRibHY5ckQtNFZ3bGFkNUQyNjVwcUw4Y1YtOHI1MlRfLUx3?oc=5", "source_name": "MarketBeat", "published_at": "2025-06-05T20:35:15+00:00", "published_display": "05 Jun 2025 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMAA Stock Price and Chart \u2014 NASDAQ:DMAA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFA3NXNhMEk4UzhUR0FxYmxHU2Y2Mm5najcyOGRuZzlBNWlseU13TFlMSkFPTjhpMXJnZ0xmb3FSbzFvX1poSm5sYUhBZ2ZUam1MTTUybXoxMzNjYUoz?oc=5", "source_name": "TradingView", "published_at": "2025-02-25T19:29:15+00:00", "published_display": "25 Feb 2025 19:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp. Completes $200 Million IPO on Nasdaq", "summary": "Drugs Made In America Acquisition Corp. (DMAAU) has successfully completed its $200 million initial public offering on Nasdaq, selling 20 million units at $10 each. The blank check company aims to pursue business combinations within the pharmaceutical industry, specifically focus", "url": "https://www.nasdaq.com/articles/drugs-made-america-acquisition-corp-completes-200-million-ipo-nasdaq", "source_name": "Nasdaq", "published_at": "2025-01-29T16:22:00", "published_display": "29 Jan 2025 16:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made in America Acquisition Corp. (DMAAU) Prices $200M IPO", "summary": "Drugs Made in America Acquisition Corp. (DMAAU) announced the pricing of its $200 million IPO, with units expected to trade on Nasdaq starting January 28, 2025. The Special Purpose Acquisition Company (SPAC) plans to merge with a pharmaceutical company focused on plant-based raw ", "url": "https://www.spacinsider.com/news/new-ipos/drugs-made-in-america-acquisition-corp-dmaau-prices-200m-ipo", "source_name": "SPACInsider", "published_at": "2025-01-27T17:40:00", "published_display": "27 Jan 2025 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Drugs Made In America Acquisition Corp (DMAA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Drugs Made In America Acquisition Corp (DMAA), focusing on its profitability and balance sheet. It notes that relevant financial data regarding cash, assets, liabilities, free cash flow, revenue, operating profit, and operation", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T17:41:30", "published_display": "18 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp", "summary": "This article provides an overview of Drugs Made In America Acquisition Corp (DMAA), including its current stock price, market capitalization, and P/E ratio. It notes that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:36", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAAR) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Drugs Made In America Acquisition Corp (DMAAR), including its stock price, market cap, and various institutional shareholdings. It lists major institutional investors and their shareholdings, as well as changes in t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaar/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:58", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAAU) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Drugs Made In America Acquisition Corp (DMAAU), detailing its current stock price, market cap, and indicating that relevant valuation data like P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. It briefly outlines t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaau/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:32", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAAU) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Drugs Made In America Acquisition Corp (DMAAU) focusing on its institutional confidence. It lists key institutional shareholders and their recent activity, showing both increases and decreases in shares held. The data highlight", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaau/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:32", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAAU) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Drugs Made In America Acquisition Corp (DMAAU), detailing various risk metrics such as volatility, maximum drawdown, and return-to-drawdown ratios. It presents a quantitative overview of the stock's risk profile based on metrics like be", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaau/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:32", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAAU) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Drugs Made In America Acquisition Corp (DMAAU), focusing on its profitability and balance sheet. However, the report indicates that relevant financial data for profitability, operational efficiency, growth potential, and shareh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaau/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:32", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBrUEd1QU54WTZiNzRJRUtaYzRsb2RkdDRnc2tfaV83NDVEdVBoVWM5bE1iRHlWU2NnTEhLWWZvZXphSHMtUVFkSm9QWmc5eGV5UUhZTGNGOGtKZldFcnpseWk5RV93cFhaVmNrY3daMW13dGlZRHcwSg?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T01:52:16+00:00", "published_display": "18 Jun 2026 01:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Drugs Made In America Acquisition Corp (DMAA), including its current market data, P/E ratio, and market capitalization. It highlights that relevant data for financial forecasting, such as EPS, Revenue, and Net Profit, have not yet be", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:25", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Drugs Made In America Acquisition Corp (DMAA), focusing on changes in institutional shareholding. It lists key shareholders and their recent activity, including increases and decreases in shares held by major invest", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:25", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Ord Shs (DMII) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTFBncnYwQkdHeW1vYVBUNU1JWS11bWxlUlR6Tk5RY2N5cWZrb0ZGamMtb01vdmpyc1gwT2cyQ1A0VkctMGhkMjRwUzNnYW0zYUZsd2ZHTTE5RE9VOTJoNENHN0hzM25ELWJBNng5WDRnY3Y?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T22:54:11+00:00", "published_display": "17 Jun 2026 22:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Drugs Made", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-17T23:39:32", "published_display": "17 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Drugs Made In America Acquisition Corp (DMAA), focusing on its PE, PB, and fair value. It notes that relevant data for these metrics have not yet been disclosed by the company. The company closed at $10.620 with a market cap of $257.8", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:25", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Drugs Made In America Acquisition Corp (DMAA), listing major shareholders and their respective proportions. It also presents institutional shareholding data over several quarters and reports on significant shareholder activities i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dmaa/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:32", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Units (DMIIU) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE1vcTZLeEdsd0J2UGplQ1JrNTJ5VTllTUpkZFJYejQ0Z1ZPVDFFTERhc3B1elNYMDMtYnc0YUY1ekhIcjI3SFhtYXdkcEJTSUtOQkhfeU1GX0p5ODZ3N0V0VkdKVG1EUndQSGtnUEptOF8xUQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T08:47:40+00:00", "published_display": "17 Jun 2026 08:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp (DMAA) and Power Analytics Global Corp Announce Definitive $1B AI Merger Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOOUdRXzBpTzM2NzlfOE1hT2hJaUxpd3VEODZ4Yjl3eDBidW9WdURwOXU3QVA4c3AxQ3lMaDdGVFhpNThiTGxpV2tRNzRMNzM0WFhwNThWOTNlX1Via0ZHay1hZVhUNlA4WW55eEM1dU1MbllHbnlOMEMtcGdmZjg2UTZ5bmJQRjVBS0J3bTFtQjJZTTFYMkdpMWNlelByX1llSXlzMkx2bmtxRU9QeUN5TC0zX3VOak1MNmtUS1J3enlHSnd6Z2ZnTmpTejBtQjl5VUwyMFY2cy0yNnc3UmJCcUM1dnVKWWtiZWpuNmV5OFI?oc=5", "source_name": "Minichart", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition to Merge With Power Analytics Global in Deal Valued Up to $1 Billion", "summary": "Drugs Made In America Acquisition (DMAA) has entered into a Definitive Merger Agreement with Power Analytics Global (PAGC), an AI and cybersecurity company. The deal values PAGC at up to $1 billion, with a floor valuation of $300 million, and is intended to take PAGC public. Post", "url": "https://www.tradingview.com/news/tradingview:e2b78c838864c:0-drugs-made-in-america-acquisition-to-merge-with-power-analytics-global-in-deal-valued-up-to-1-billion/", "source_name": "TradingView", "published_at": "2026-05-05T23:38:43", "published_display": "05 May 2026 23:38", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMAAR Price History for Drugs Made IN America Acquisition Corp. Rights Stock", "summary": "This Barchart.com page provides detailed price history information for Drugs Made IN America Acquisition Corp. Rights (DMAAR) stock. It includes tabs for end-of-day prices, latest trades, and corporate actions, with options for members to download historical data. The page also f", "url": "https://www.barchart.com/stocks/quotes/DMAAR/price-history", "source_name": "Barchart", "published_at": "2026-04-21T08:09:32", "published_display": "21 Apr 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made in America Acquisition Corp. signs LOI for de-SPAC with Power Analytics", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOVGhZakR2ZW5iU2FSYzNCU2xCbVlaWFFRb3NtZmlhS1hNR3lTR1pPUk5xWktubmg3NV9MaUM4VGRIUkRFZ2o5VGthZTIyci1RcWhDSkRIaGFHWTNMZmRaZm41RUZfT0hDSk83YmYtemdTbmxxT2lZci1TN3NwWVRwV3Q2akE2a0ZtOHNVRE93VEFoYzFBRGZvb19NMGp5eXE1cTA2NlhaZEM1YVBDZEN4UzhUUURWWm94VUJZZkVTR0tmbkMyU0lxMTZKMmw1Vmk4ZXc?oc=5", "source_name": "Investing.com", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prudential Earnings: Headline Numbers Make the Market Skeptical; Shares Fairly Valued", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOLXpWLThmYURNcnJBLXZQNTlRUy1NSmQ4NkVVX0pQRzlfUFFtVFJkNDJqN1FFYWZLWS1xSmd5S3dNUU42cjFLOUdiWTkxdXhvZXg1UlFtZmtVZG1qN2w4QWxXZEJsbFJ2QUQtVUIxMWJ4Z1l3djBiNFp3MEdhbkh6cUtlWVB5b2RNZXZudmhPbWI3RkF0NmhxdF9aQmppbUFHOThtZDlBU3Vsak9fX0pKUGotdHNBaDkzODRZbGdUUVc?oc=5", "source_name": "Morningstar", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMAAR SEC Filings - Drugs Made In Amer Acqutn Corp 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTFA0ZEdQMlQ3Nnl0dXJYYUdnYWQ3RkZ0VEtjNGYtd09oMUkzbUZqVVRJaE1BMnM2R1h0NlQ0Tk16OUVraHI0cTBkaDk0anRZWmlWTXZTMk1TdFA?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-06T15:37:01+00:00", "published_display": "06 Mar 2026 15:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition (NASDAQ:DMAA) Trading Up 0.2% - Time to Buy?", "summary": "Drugs Made In America Acquisition (NASDAQ: DMAA) rose 0.2% to $10.40 during midday trading on Tuesday but traded well below its average daily volume. Analyst sentiment is predominantly negative, with Weiss Ratings reaffirming a \"Sell (D-)\" rating. Despite this, several institutio", "url": "https://www.marketbeat.com/instant-alerts/drugs-made-in-america-acquisition-nasdaqdmaa-trading-up-02-time-to-buy-2026-01-14/", "source_name": "MarketBeat", "published_at": "2026-01-14T07:58:29", "published_display": "14 Jan 2026 07:58", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) is largely controlled by institutional shareholders who own 79% of the company", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPa3VmcmlGOGwwYUlSWmNsZzRsMnU1b3hPWENLZkRydklBT25SUmRGMXg1Q2h3TnhoWUJGekNBQW5oUzlGOGNQam9RRTg4UkpvUDRHVWtBdDJwVzUzcEhNR3FoWDlWWkFUZFpZZDBsaHVXQ01PUWJ3ZlpuV1R0djRnSW5QcVhzUQ?oc=5", "source_name": "Market source", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. Announces the Separate Trading of its Ordinary Shares and Rights Commencing December 3, 2025", "summary": "Drugs Made In America Acquisition II Corp. announced that, effective December 3, 2025, holders of its units from the initial public offering can trade ordinary shares and rights separately on the Nasdaq Global Market. Each unit comprises one ordinary share and a right to receive ", "url": "https://www.8newsnow.com/business/press-releases/globenewswire/9596034/drugs-made-in-america-acquisition-ii-corp-announces-the-separate-trading-of-its-ordinary-shares-and-rights-commencing-december-3-2025", "source_name": "KLAS 8 News Now", "published_at": "2025-12-03T06:34:00", "published_display": "03 Dec 2025 06:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp. SEC 10-Q Report", "summary": "Drugs Made In America Acquisition Corp. (DMAA) has released its Q3 2025 Form 10-Q report, detailing financial performance and operational progress. The blank check company, focused on the pharmaceutical industry, reported a net income of $2.18 million for the quarter, primarily f", "url": "https://www.tradingview.com/news/tradingview:8cc2be0240140:0-drugs-made-in-america-acquisition-corp-sec-10-q-report/", "source_name": "TradingView", "published_at": "2025-11-19T05:37:23", "published_display": "19 Nov 2025 05:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. SEC 10-Q Report", "summary": "Drugs Made In America Acquisition II Corp. (DMIIU), a blank check company, has released its Form 10-Q report for Q3 2025, detailing a net loss of $46,158 for the quarter and $143,558 for the nine months ended September 30, 2025. The company, which completed its IPO in September 2", "url": "https://www.tradingview.com/news/tradingview:5f14fb6106821:0-drugs-made-in-america-acquisition-ii-corp-sec-10-q-report/", "source_name": "TradingView", "published_at": "2025-11-19T05:37:23", "published_display": "19 Nov 2025 05:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMIIU Stock Price, News & Analysis | Drugs Made In America Acquisition II", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTFBGU2Y4dVVTM3gwWEJyem96UGtIbWZEelBIZ184NDMyNHNWTkxVc09ncnFWZUNEZDhuYmJZMVRaM0hiVUl1VUZhLWFmSWhJM2VpbFJJaQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-09-25T11:28:45+00:00", "published_display": "25 Sep 2025 11:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition (DMAA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5va2pWcm8xT3NBTnQxNjJVUW0zck9FUXJHcGNSNjV3SV9RVHRpZlgybHRwY2hPVmdVTy0zbUY5aFZBazhsUTR2X1VoWG1WbnRJS3RfOXRMd1JOZw?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-24T23:55:47+00:00", "published_display": "24 Jul 2025 23:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition (DMAA) Institutional Ownership 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE5UYkV5QVpnRktjRm5EWTNYcndENXM5MXpsb2xRbmE2elAyRWJPa2lyMHl2WmZlcng2MlNlMHRPNk5aekNjM0dRVTF1ZUtwUUVhVDdaekgzdVRibHY5ckQtNFZ3bGFkNUQyNjVwcUw4Y1YtOHI1MlRfLUx3?oc=5", "source_name": "MarketBeat", "published_at": "2025-06-05T20:35:15+00:00", "published_display": "05 Jun 2025 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMAA Stock Price and Chart \u2014 NASDAQ:DMAA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFA3NXNhMEk4UzhUR0FxYmxHU2Y2Mm5najcyOGRuZzlBNWlseU13TFlMSkFPTjhpMXJnZ0xmb3FSbzFvX1poSm5sYUhBZ2ZUam1MTTUybXoxMzNjYUoz?oc=5", "source_name": "TradingView", "published_at": "2025-02-25T19:29:15+00:00", "published_display": "25 Feb 2025 19:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Corp. Completes $200 Million IPO on Nasdaq", "summary": "Drugs Made In America Acquisition Corp. (DMAAU) has successfully completed its $200 million initial public offering on Nasdaq, selling 20 million units at $10 each. The blank check company aims to pursue business combinations within the pharmaceutical industry, specifically focus", "url": "https://www.nasdaq.com/articles/drugs-made-america-acquisition-corp-completes-200-million-ipo-nasdaq", "source_name": "Nasdaq", "published_at": "2025-01-29T16:22:00", "published_display": "29 Jan 2025 16:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made in America Acquisition Corp. (DMAAU) Prices $200M IPO", "summary": "Drugs Made in America Acquisition Corp. (DMAAU) announced the pricing of its $200 million IPO, with units expected to trade on Nasdaq starting January 28, 2025. The Special Purpose Acquisition Company (SPAC) plans to merge with a pharmaceutical company focused on plant-based raw ", "url": "https://www.spacinsider.com/news/new-ipos/drugs-made-in-america-acquisition-corp-dmaau-prices-200m-ipo", "source_name": "SPACInsider", "published_at": "2025-01-27T17:40:00", "published_display": "27 Jan 2025 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 82, "total_relevant": 32, "sentiment_summary": {"positive": 1, "negative": 1, "neutral": 30, "score": 51, "total": 32, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 91, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 15.95, "count": 29}, {"event": "general", "label": "Market update", "weight": 1.1, "count": 2}, {"event": "earnings", "label": "Earnings", "weight": 0.9, "count": 1}], "positive_events": 1, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 10.63, "latest_week": "2026-06-19", "one_week_move": 0.1, "four_week_move": 0.3, "twelve_week_move": 1.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.845191, "market_dynamics_buy_signal": false, "relative_strength": -15.508083, "fair_value_gap": 3.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "positive", "expectation_probability": 67.6266, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.1% over one week, +0.3% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 53, "badges": [], "opportunities": [], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 15}, {"label": "TradingView", "count": 4}, {"label": "MarketBeat", "count": 3}, {"label": "Stock Titan", "count": 2}, {"label": "Minichart", "count": 1}, {"label": "Barchart", "count": 1}, {"label": "Investing.com", "count": 1}, {"label": "Morningstar", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 32}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 29}, {"label": "Market update", "count": 2}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "91/100 classification confidence."}, {"label": "Company focus", "value": "32", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.1% over one week, +0.3% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Drugs Made In America Acquisition Corp (DMAA) Financial Health: Profitability & Balance Sheet Analysis"}], "updated_at": "2026-06-22T20:56:58.258980+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}